Compare Divis Laboratories with Glenmark Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DIVIS LABORATORIES vs GLENMARK PHARMA - Comparison Results

DIVIS LABORATORIES     Change

Established in the year 1990, Divi's Laboratories has been focusing on CRAMS and is an established player in the custom chemical synthesis (CCS) and API/Intermediate segment. Around 50% of Divi's revenues are derived from custom manufacturing for glo... More

GLENMARK PHARMA 
   Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DIVIS LABORATORIES GLENMARK PHARMA DIVIS LABORATORIES/
GLENMARK PHARMA
 
P/E (TTM) x 59.7 15.6 383.3% View Chart
P/BV x 13.8 2.6 537.8% View Chart
Dividend Yield % 0.4 0.4 112.9%  

Financials

 DIVIS LABORATORIES   GLENMARK PHARMA
EQUITY SHARE DATA
    DIVIS LABORATORIES
Mar-19
GLENMARK PHARMA
Mar-19
DIVIS LABORATORIES/
GLENMARK PHARMA
5-Yr Chart
Click to enlarge
High Rs1,639712 230.4%   
Low Rs1,115484 230.6%   
Sales per share (Unadj.) Rs186.3349.6 53.3%  
Earnings per share (Unadj.) Rs51.032.8 155.4%  
Cash flow per share (Unadj.) Rs57.344.3 129.3%  
Dividends per share (Unadj.) Rs16.002.00 800.0%  
Dividend yield (eoy) %1.20.3 347.2%  
Book value per share (Unadj.) Rs261.8198.6 131.8%  
Shares outstanding (eoy) m265.47282.17 94.1%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x7.41.7 432.4%   
Avg P/E ratio x27.018.2 148.3%  
P/CF ratio (eoy) x24.013.5 178.2%  
Price / Book Value ratio x5.33.0 174.9%  
Dividend payout %31.46.1 514.7%   
Avg Mkt Cap Rs m365,592168,625 216.8%   
No. of employees `00011.812.0 98.4%   
Total wages/salary Rs m5,42320,561 26.4%   
Avg. sales/employee Rs Th4,175.18,196.0 50.9%   
Avg. wages/employee Rs Th457.71,708.1 26.8%   
Avg. net profit/employee Rs Th1,141.8768.5 148.6%   
INCOME DATA
Net Sales Rs m49,46398,655 50.1%  
Other income Rs m1,5562,081 74.8%   
Total revenues Rs m51,019100,736 50.6%   
Gross profit Rs m18,71815,858 118.0%  
Depreciation Rs m1,6893,259 51.8%   
Interest Rs m353,346 1.0%   
Profit before tax Rs m18,55111,335 163.7%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m01,672 0.0%   
Tax Rs m5,0233,756 133.7%   
Profit after tax Rs m13,5279,250 146.2%  
Gross profit margin %37.816.1 235.4%  
Effective tax rate %27.133.1 81.7%   
Net profit margin %27.39.4 291.7%  
BALANCE SHEET DATA
Current assets Rs m46,50166,968 69.4%   
Current liabilities Rs m8,46840,211 21.1%   
Net working cap to sales %76.927.1 283.5%  
Current ratio x5.51.7 329.7%  
Inventory Days Days13183 157.0%  
Debtors Days Days8681 105.7%  
Net fixed assets Rs m25,79733,322 77.4%   
Share capital Rs m531282 188.1%   
"Free" reserves Rs m68,96255,770 123.7%   
Net worth Rs m69,49356,052 124.0%   
Long term debt Rs m035,738 0.0%   
Total assets Rs m80,383132,888 60.5%  
Interest coverage x531.04.4 12,102.8%   
Debt to equity ratio x00.6 0.0%  
Sales to assets ratio x0.60.7 82.9%   
Return on assets %16.99.5 178.0%  
Return on equity %19.516.5 118.0%  
Return on capital %26.717.8 150.1%  
Exports to sales %00-   
Imports to sales %24.60-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs m12,187NA-   
Fx inflow Rs m41,23862,998 65.5%   
Fx outflow Rs m12,40522,859 54.3%   
Net fx Rs m28,83340,140 71.8%   
CASH FLOW
From Operations Rs m9,54313,242 72.1%  
From Investments Rs m-6,854-6,990 98.1%  
From Financial Activity Rs m-2,459-7,387 33.3%  
Net Cashflow Rs m230-2,971 -7.7%  

Share Holding

Indian Promoters % 52.0 48.3 107.7%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 11.8 6.9 171.0%  
FIIs % 19.0 34.4 55.2%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.2 10.5 163.8%  
Shareholders   31,796 56,727 56.1%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DIVIS LABORATORIES With:   STERLING BIOTECH  SANOFI INDIA  ALKEM LABORATORIES  ORCHID PHARMA  PFIZER  

Compare DIVIS LABORATORIES With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Trades Marginally Higher; Dow Futures Up by 6 Points(12:30 pm)

Share markets in India are presently trading marginally higher. The BSE Sensex is trading up by 140 points, up 0.3% at 49,538 levels.

Related Views on News

GLENMARK PHARMA Announces Quarterly Results (1QFY21); Net Profit Up 132.5% (Quarterly Result Update)

Sep 1, 2020 | Updated on Sep 1, 2020

For the quarter ended June 2020, GLENMARK PHARMA has posted a net profit of Rs 3 bn (up 132.5% YoY). Sales on the other hand came in at Rs 23 bn (up 0.9% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

DIVIS LABORATORIES Announces Quarterly Results (1QFY21); Net Profit Up 84.1% (Quarterly Result Update)

Aug 10, 2020 | Updated on Aug 10, 2020

For the quarter ended June 2020, DIVIS LABORATORIES has posted a net profit of Rs 5 bn (up 84.1% YoY). Sales on the other hand came in at Rs 17 bn (up 50.0% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

DIVIS LABORATORIES Announces Quarterly Results (4QFY20); Net Profit Up 35.4% (Quarterly Result Update)

Jun 8, 2020 | Updated on Jun 8, 2020

For the quarter ended March 2020, DIVIS LABORATORIES has posted a net profit of Rs 4 bn (up 35.4% YoY). Sales on the other hand came in at Rs 14 bn (up 9.5% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

GLENMARK PHARMA Announces Quarterly Results (3QFY20); Net Profit Up 64.0% (Quarterly Result Update)

Feb 19, 2020 | Updated on Feb 19, 2020

For the quarter ended December 2019, GLENMARK PHARMA has posted a net profit of Rs 2 bn (up 64.0% YoY). Sales on the other hand came in at Rs 27 bn (up 7.1% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

DIVIS LABORATORIES Announces Quarterly Results (3QFY20); Net Profit Down 4.9% (Quarterly Result Update)

Feb 6, 2020 | Updated on Feb 6, 2020

For the quarter ended December 2019, DIVIS LABORATORIES has posted a net profit of Rs 4 bn (down 4.9% YoY). Sales on the other hand came in at Rs 14 bn (up 3.5% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

More Views on News

Most Popular

'Essential' Smallcap Stock Recommendations(Profit Hunter)

Jan 8, 2021

The smallcap rally has enough steam left in it. If you haven't joined yet, it is still not too late.

Is Nifty Forming a Top(Fast Profits Daily)

Jan 8, 2021

The charts are telling the bulls to be cautious.

Why Gold Hit Lower Circuit(Fast Profits Daily)

Jan 11, 2021

Were you shocked that bullion prices hit lower circuits on Friday on the MCX? Find out why it happened...

A Rare Chance to Invest in Potential Multibaggers in 2021(Profit Hunter)

Jan 11, 2021

Our ace stock picker is ready to capitalise on a big growth opportunity.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

DIVIS LABORATORIES SHARE PRICE


Jan 20, 2021 03:36 PM

TRACK DIVIS LABORATORIES

  • Track your investment in DIVIS LABORATORIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DIVIS LABORATORIES

DIVIS LABORATORIES 8-QTR ANALYSIS

COMPARE DIVIS LABORATORIES WITH

MARKET STATS